{"id":51737,"date":"2025-12-21T21:30:12","date_gmt":"2025-12-21T13:30:12","guid":{"rendered":"https:\/\/flcube.com\/?p=51737"},"modified":"2025-12-21T21:30:13","modified_gmt":"2025-12-21T13:30:13","slug":"sanegenebios-inhbe-sirna-wins-china-ind-for-obesity-as-first-rnai-target","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51737","title":{"rendered":"SanegeneBio\u2019s INHBE siRNA Wins China IND for Obesity as First RNAi Target"},"content":{"rendered":"\n

SanegeneBio<\/strong>, a clinical\u2011stage RNAi therapeutics company, announced that China\u2019s National Medical Products Administration (NMPA)<\/strong> approved its Investigational New Drug (IND) application<\/strong> for SGB\u20117342<\/strong>, an experimental siRNA medicine targeting Inhibin Beta E (INHBE)<\/strong> for the treatment of obesity<\/strong>. The drug is a GalNAc\u2011conjugated siRNA<\/strong> designed to suppress INHBE mRNA in hepatocytes, reducing Activin E levels and promoting selective lipolysis while preserving lean body mass.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Approval Date<\/strong><\/td>16\u202fDec\u202f2025<\/td><\/tr>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Product<\/strong><\/td>SGB\u20117342 (INHBE\u2011targeted siRNA)<\/td><\/tr>
Indication<\/strong><\/td>Obesity (metabolic disease)<\/td><\/tr>
Mechanism<\/strong><\/td>GalNAc\u2011conjugated siRNA suppresses INHBE mRNA in liver<\/td><\/tr>
Innovation<\/strong><\/td>First RNAi therapy<\/strong> targeting INHBE globally<\/td><\/tr>
Development Stage<\/strong><\/td>IND\u2011ready; Phase\u202f1 initiation expected Q1\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism of Action<\/h2>\n\n\n\n
Attribute<\/th>SGB\u20117342<\/th>Scientific Rationale<\/th><\/tr><\/thead>
Target<\/strong><\/td>INHBE mRNA (liver\u2011expressed)<\/td>INHBE loss\u2011of\u2011function linked to favorable metabolic profile<\/td><\/tr>
Payload<\/strong><\/td>GalNAc\u2011conjugated siRNA<\/td>Enables hepatocyte\u2011specific delivery<\/td><\/tr>
Effect<\/strong><\/td>Reduces Activin E protein synthesis<\/td>Decreases adipose tissue ALK7 receptor signaling<\/td><\/tr>
Outcome<\/strong><\/td>Selective lipolysis, reduced fat mass, improved insulin sensitivity<\/td>Preserves lean muscle mass<\/td><\/tr>
Administration<\/strong><\/td>Single subcutaneous injection (preclinical)<\/td>Potent and durable knockdown demonstrated<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Preclinical Data Summary<\/h2>\n\n\n\n
Study<\/th>Key Findings<\/th><\/tr><\/thead>
Dosing<\/strong><\/td>Single SC administration<\/td><\/tr>
INHBE Knockdown<\/strong><\/td>Potent and durable mRNA suppression in liver<\/td><\/tr>
Weight Reduction<\/strong><\/td>Significant body weight loss in animal models<\/td><\/tr>
Body Composition<\/strong><\/td>Improved composition with preserved lean muscle mass<\/strong><\/td><\/tr>
Safety<\/strong><\/td>Favorable safety and tolerability profile<\/td><\/tr>
Differentiation<\/strong><\/td>Targeted metabolic pathway<\/strong> vs. broad appetite suppression<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity & Competitive Landscape<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Context<\/th><\/tr><\/thead>
Obesity Prevalence<\/strong><\/td>900\u202fmillion<\/strong> adults globally; 150\u202fmillion<\/strong> in China<\/td>High unmet need for targeted therapy<\/td><\/tr>
Current Standard<\/strong><\/td>GLP\u20111\/GIP agonists (Wegovy, Zepbound)<\/td>Systemic appetite suppression; muscle mass loss common<\/td><\/tr>
RNAi Market<\/strong><\/td>$5\u202fbillion<\/strong> (2025); projected $15\u202fbillion<\/strong> by 2030<\/td>Growing interest in hepatic\/metabolic RNAi<\/td><\/tr>
INHBE Advantage<\/strong><\/td>Selective fat loss<\/strong> with lean mass preservation<\/td>Addresses key limitation of current obesity drugs<\/td><\/tr>
Peak Sales Potential<\/strong><\/td>\u00a53\u20115\u202fbillion<\/strong> (\u2248\u202fUS$420\u2011700\u202fM) by 2033<\/td>10\u201115% share of China obesity market if approved<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n